SIG
CRL icon

Stonegate Investment Group’s Charles River Laboratories CRL Stock Holding History

Stonegate Investment Group’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,002
Closed -$207K – 413
2024
Q2 		$207K Buy
1,002
+26
+3% +$5.89K 0.01% 335
2024
Q1 		$264K Buy
+976
New +$233K 0.01% 272
2023
Q4 		– Sell
-1,025
Closed -$201K – 348
2023
Q3 		$201K Sell
1,025
-141
-12% -$28.9K 0.01% 279
2023
Q2 		$245K Buy
1,166
+61
+6% +$12.1K 0.01% 276
2023
Q1 		$223K Buy
1,105
+85
+8% +$19.3K 0.01% 286
2022
Q4 		$222K Sell
1,020
-88
-8% -$19.2K 0.01% 280
2022
Q3 		$218K Buy
1,108
+112
+11% +$24.2K 0.01% 253
2022
Q2 		$213K Buy
996
+87
+10% +$21.3K 0.01% 264
2022
Q1 		$258K Buy
909
+244
+37% +$75.2K 0.01% 219
2021
Q4 		$251K Buy
+665
New +$258K 0.01% 228

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.6B AUM 15.71% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
EC
Eminence Capital New York $4.36B AUM 3.1% 1-Year Est. Return

Stonegate Investment Group's CRL Position: Q3 2024 in Review

Stonegate Investment Group sold out of Charles River Laboratories (CRL) in Q3 2024, closing a stake of 1,002 shares — an estimated $207K sold.

Stonegate Investment Group first reported a position in CRL in Q4 2021 and held it in 10 quarters. The position peaked at $264K in Q1 2024. 628 funds tracked by Wall St. Rank hold CRL as of Q3 2024.

  • Stonegate Investment Group reported no remaining Charles River Laboratories position as of Q3 2024 after selling out during the quarter.
  • Stonegate Investment Group sold 1,002 Charles River Laboratories shares in Q3 2024, an estimated $207K.
  • Stonegate Investment Group first reported a position in Charles River Laboratories in Q4 2021 and held it in 10 quarters.
  • Stonegate Investment Group's Charles River Laboratories position peaked at $264K in Q1 2024.
  • 628 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2024.

Based on Stonegate Investment Group's 13F filing for Q3 2024, filed 17 Oct 2024.